ITGAX and neoplasm: Considering the higher content of TAMs in MC38 tumors compared with B16F10 tumors, we speculate that—when used therapeutically—the injected DCs activate T cells to initiate an anti-tumor response while exerting tumoricidal effects through the accumulation of CD11c+ cells.